Nicola Veronese - Frailty and Cardiovascular Diseases: Research into an Elderly Population

Advances in Experimental Medicine and Biologypresents multidisciplinary and dynamic findings in the broad fields of experimental medicine and biology. The wide variety in topics it presents offers readers multiple perspectives on a variety of disciplines including neuroscience, microbiology, immunology, biochemistry, biomedical engineering and cancer research.

Advances in Experimental Medicine and Biologyhas been publishing exceptional works in the field for over 30 years and is indexed in SCOPUS; Medline (PubMed); Journal Citation Reports/Science Edition; Science Citation Index Expanded (SciSearch) (Web of Science); EMBASE; BIOSIS; Reaxys; EMBiology; Chemical Abstracts Service (CAS); Pathway Studio. The series also provides scientists with up to date information on emerging topics and techniques.

2018 Impact Factor: 2.126.

More information about this series at http://www.springer.com/series/5584

This Springer imprint is published by the registered company Springer Nature Switzerland AG

The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

Frailty and cardiovascular diseases (CVD) are two common conditions in the elderly, highly affecting clinical outcomes in older people. Epidemiological studies suggest that CVD are among the most relevant contributors in the development of frailty. At the same time, increasing research is showing that frailty can be considered as a potential CVD risk factor, independently from other CVD risk factors. The association between CVD and frailty is probably due to the shared etiological factors, including low-grade inflammation, cellular senescence, and endocrine dysregulation. The early detection of frailty is therefore important in the management of patients with CVD or in people who are at high risk of having CVD, such as frail patients. In this regard, the use of a comprehensive geriatric assessment (CGA) seems to be essential for better taking care of older people with CVD or in those at high risk for developing CVD.

In this book, we will offer to the reader an overview of the current evidence regarding the epidemiology of frailty and CVD and their co-existence in terms of epidemiological research. Moreover, some chapters will be dedicated to exploring the underlying pathophysiology, with a special interest on inflammation and oxidative stress. Finally, the clinical importance of frailty in CVD and vice versa will be discussed. A last part will be dedicated to the treatment of frailty and CVD and the newer topics of interest in this field.

Therefore, this book will offer an up-to-date review on the potential relationship between frailty and CVD, which may represent a novel topic in geriatric medicine. Accordingly, the book will be relevant to a wide range of clinicians. The authorship will include many of the best known and widely published experts in their respective fields.